New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers SOMERVILLE, Mass. / Jun 02, 2025 / Business Wire / bluebird bio (NASDAQ: BLUE)... Read More